Lung Cancer
Clinical Data Suggest Potential Versatility of ALIMTA (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Published in Cancer Weekly, June 19th, 2007
ALIMTA(R) (pemetrexed for injection) showed additional utility in the treatment of the most diagnosed type of cancer(i), according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). Results from a Phase III study suggest that a first-line ALIMTA-based regimen may deliver less toxicity than a commonly used therapy in advanced non-small cell lung cancer (NSCLC). ALIMTA is manufactured and marketed by Eli Lilly and Company.
A prospective, randomized, multicenter Phase III study was conducted to compare ALIMTA plus carboplatin with the commonly used regimen of GEMZAR(R) (gemcitabine HC1 for injection) plus carboplatin...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-06-19)
More Articles from Cancer Weekly
- Breast Cancer
Study suggests newer breast cancer drug may protect heart - Cancer Gene Therapy
Neuronal Activity Gives Clues to Working Memory - Lymphoma
Adding radioimmunotherapy to chemo may help patients with lymphoma - Molecular Imaging
Every moment counts: Predicting treatment responses earlier for brain tumor patients - Monoclonal Antibodies
Phase II study shows combination improves survival of metastatic melanoma patients - Adverse Drug Reactions
Vical Demonstrates Safety and Tolerability of IL-2 DNA Delivery with Electroporation - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
